Zynerba Pharmaceuticals Changes Annual Meeting of Shareholders to Virtual-Only Format in Response to COVID-19 Pandemic
May 21 2020 - 08:00AM
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in
innovative pharmaceutically-produced transdermal cannabinoid
therapies for rare and near-rare neuropsychiatric disorders, today
announced that due to public health guidance related to the
coronavirus (COVID-19) pandemic and for the safety of participants
its Annual Meeting has been changed to a virtual format only.
As previously announced, the Annual Meeting will be
held on June 10, 2020 at 8:00 a.m. Eastern Time for shareholders of
record as of the close of business on April 14, 2020. However,
participants will not be able to attend the Annual Meeting in
person. Both stockholders of record and street name stockholders
will need to register in advance by following the instructions
below in order to be able to attend the Annual Meeting via live
audio webcast, submit their questions during the meeting and vote
their shares electronically at the Annual Meeting.
Instructions for Participating in the
Annual Meeting
In order to participate in the 2020 Annual Meeting
via live audio webcast, you must register at
www.viewproxy.com/zynerbapharm/2020 by 11:59 p.m. Eastern Time
on June 7, 2020. If you are a registered holder, you must register
using your name, address and phone number as it appears on your
Notice of Internet Availability of Proxy Materials or your proxy
card (if you received a printed copy of the proxy materials).
A Virtual Control Number will be assigned to you in a
confirmation email following your registration.
If you hold your shares beneficially through a bank
or broker, you must provide a legal proxy from your bank or broker
during registration and you will be assigned a Virtual Control
Number in order to vote your shares during the 2020 Annual Meeting.
If you are unable to obtain a legal proxy to vote your shares, you
will still be able to attend the 2020 Annual Meeting (but will not
be able to vote your shares) so long as you demonstrate proof of
stock ownership. Further instructions on how to attend the Annual
Meeting via the internet, including how to demonstrate proof of
stock ownership and how to vote your shares electronically at the
Annual Meeting are posted on
www.viewproxy.com/zynerbapharm/2020 under Frequently Asked
Questions (FAQ).
The Annual Meeting live audio webcast will begin
promptly at 8:00 a.m. Eastern Time on June 10, 2020. We encourage
you to access the meeting prior to the start time. Online check-in
will begin at 7:30 a.m. Eastern Time and you should allow ample
time for the check-in procedures. We will have technicians
available to assist you with access to the Annual Meeting. If
you encounter difficulties accessing the Annual Meeting live audio
webcast during the check-in or meeting time, please email
VirtualMeeting@viewproxy.com or call 1-866-612-8937.
Voting Methods
Whether or not shareholders plan to access the
Annual Meeting electronically, the Company encourages you to vote
in advance of the Annual Meeting by using one of the methods set
forth in the proxy materials previously distributed, so that your
vote will be counted even if you later decide not to attend the
virtual Annual Meeting. Shareholders who have already voted
do not need to take any further voting action unless they wish to
change their vote.
About Zynerba Pharmaceuticals,
Inc.
Zynerba Pharmaceuticals is the leader in
pharmaceutically-produced transdermal cannabinoid therapies for
rare and near-rare neuropsychiatric disorders. We are committed to
improving the lives of patients and their families living with
severe, chronic health conditions including Fragile X syndrome,
autism spectrum disorder, 22q11.2 deletion syndrome, and a
heterogeneous group of rare and ultra-rare epilepsies known as
developmental and epileptic encephalopathies. Learn more at
www.zynerba.com and follow us on Twitter at
@ZynerbaPharma.
Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. We may, in some cases, use terms such as
“predicts,” “believes,” “potential,” “proposed,” “continue,”
“estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,”
“could,” “might,” “will,” “should” or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Such statements are subject to numerous
important factors, risks and uncertainties that may cause actual
events or results to differ materially from the Company’s current
expectations. These and other risks are described in the
Company’s periodic reports, including the annual report on Form
10-K, quarterly reports on Form 10-Q and current reports on Form
8-K, filed with or furnished to the Securities and Exchange
Commission and available at www.sec.gov. Any forward-looking
statements that the Company makes in this press release speak only
as of the date of this press release. The Company assumes no
obligation to update forward-looking statements whether as a result
of new information, future events or otherwise, after the date of
this press release.
Investor ContactWilliam Roberts,
Vice President, Investor Relations and Corporate
CommunicationsZynerba Pharmaceuticals484.581.7489
robertsw@zynerba.com
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Feb 2024 to Mar 2024
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Mar 2023 to Mar 2024